Head and Neck Cancer Drugs Market Size to Surpass US$ 2.99 BN by 2030

The global head and neck cancer drugs market size is expected to surpass around US$ 2.99 billion by 2030 and predicted to grow at a compound annual growth rate (CAGR) of 7.9% between 2022 to 2030.

The global head and neck cancer drugs market size was estimated at US$ 1.62 billion in 2022. Head and neck cancer is a cancer of the mouth, sinuses, nose, or throat. It starts in the squamous cells that line the head and neck mucosal surfaces. It is also called squamous cell carcinomas of the head and neck. It starts in the salivary glands, sinuses, or nerves in the head and neck. It is less common than squamous cell carcinomas. It can be formed in the oral cavity, throat, voice box, Paranasal sinuses and nasal cavity, and salivary gland. Smoking is the primary reason behind head and neck cancer. Alcohol and tobacco use are important risk factors for head and neck cancers.

Get the sample copy of this report@ https://www.precedenceresearch.com/sample/1474

People who consume both tobacco and alcohol are at greater risk of developing these cancers. The drugs approved by the Food and Drug Administration (FDA) for head and neck cancer are Bleomycin Sulfate, Cetuximab, Docetaxel, Erbitux, Hydrea, Hydroxyurea, Keytruda, Methotrexate Sodium, Nivolumab, Opdivo, Pembrolizumab, Taxotere (Docetaxel), and Trexall (Methotrexate Sodium). Radiation therapy combines surgery and chemotherapy for advanced-stage head and neck cancer. Chemotherapy uses drugs to destroy cancer cells. For head and neck cancers, chemotherapy is combined with surgery, radiation therapy, or both. Chemotherapy drugs used to treat head and neck cancer includes cisplatin. Carboplatin. docetaxel (Taxotere®). 

Growth factors 

The global market is majorly driven by the increasing number of malignant tumors that develop around the throat, nose, mouth, salivary glands, and larynx. Chemotherapy is used in combination with other therapies for the treatment of head and neck cancer. The rising incidence of head and neck cancer significantly contributes to market growth. The growing consumption of alcohol and tobacco positively influences market growth.

The Epstein-Barr virus (EBV) and human papillomavirus (HPV) infection catalyze the demand for head and neck cancer drugs. It is estimated that males are affected twice as much as females. These numbers propel the growth of the global head and neck cancer drugs market. The surging expenditure in research and development activities by the top market players drives the market growth.

The widespread availability of head and neck cancer drugs such as Atezolizumab, Afatinib, and Ipilimumab favors market growth. The advancements in non-surgical procedures and therapies create a positive outlook for the market. The rapid adoption of immunotherapy and targeted therapy boosts market growth. The availability of advanced diagnostic tools to diagnose cancer positively influences market growth.

The rising awareness among the population regarding the benefits of these drugs catalyzes market growth. Developing effective and innovative drugs to treat cancer propels market growth. The increasing healthcare expenditure and rapidly growing biopharmaceutical industry augment the market’s growth.

The escalating penetration of online pharmacies accelerates market growth. Developmental strategies such as partnerships, adoption of advanced technologies, and new product launches create a positive market outlook.  

Report Highlights: 

  • Based on the treatment type, chemotherapy dominated the market and accounted for the largest revenue share due to the increasing adoption of chemotherapy in combination with radiation therapy. The rising uptake of combination therapies to treat head and neck cancer catalyzes segment growth. There are several head and neck cancer drugs available on the market. The increasing prevalence of head and neck cancer and the growing adoption of chemotherapy foster the growth of this segment. Immunotherapy is expected to witness a promising CAGR in the coming years due to its usage in cancer treatment. The rising awareness among patients regarding the benefits of immunotherapy boosts the growth of this segment. The growing approval of immunotherapy drugs drives the segment's growth.  
  • Based on the sales channel, retail pharmacies dominated the market and accounted for the largest revenue share due to the rising penetration of retail pharmacies. Retail pharmacies are a popular type of sales channel. The growing coverage of these pharmacies propels the market growth. Online pharmacies are the fastest-growing segment due to the increasing penetration of the internet and smartphones. The growing popularity of online pharmacies is driving the growth of this segment. 

Ask Here for Customization@ https://www.precedenceresearch.com/customization/1474

Market Report Scope

Report Coverage

Details

Market Size In 2022

US$ 1.62 Billion

Market Size By 2030

US$ 2.99 Billion

Growth Rate From 2022 to 2030

CAGR of 7.9%

Largest Market

North America

Base Year

2022

Forecast Period

2023 to 2030

Segments Covered         

  • AstraZeneca PLC
  • Bristol-Myers Squibb Company
  • Eli Lilly and Company
  • Fortress Biotech, Inc
  • F. Hoffmann-La Roche Ltd.
  • Immutep Limited
  • Merck & Co., Inc.
  • Merck KGaA
  • Novartis AG
  • Pfizer Inc.

By Treatment

  • Targeted Therapy
  • Chemotherapy
  • Radiation Therapy
  • Immunotherapy

By Sales Channels

  • Retail Pharmacies
  • Hospital Pharmacies
  • Online Pharmacies

Regions Covered

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East & Africa 

 

Regional snapshots 

Based on the region, North America dominated the market and accounted for the largest revenue share. It is expected to maintain its dominance in the coming years. This is due to the region's increasing prevalence of head and neck cancer. In line with this, the presence of sophisticated healthcare infrastructure and improved access to advanced diagnostic devices significantly contributes to regional market growth. Furthermore, the increased healthcare expenditure and favorable reimbursement policies drive the growth of the North American region's head and neck cancer drugs market. On the other hand, Asia Pacific is expected to witness a promising CAGR in the coming years due to the presence of a vast population. The increasing prevalence of head and neck cancer and rising consumption of alcohol and tobacco positively influence market growth across the region. The growing awareness about the availability of head and neck cancer drugs catalyzes market growth. The rising healthcare expenditure and the surging awareness towards the early diagnosis of cancer propel the market growth. The escalating demand for advanced therapeutics bolsters market growth across the region.

Market Dynamics for Head and Neck Cancer Drugs: 

Market Driver: Increase in prevalence of head & neck cancer 

The increasing prevalence of head and neck cancer significantly contributes to global market growth. In line with this, the rising demand for combination therapy and the growing research and development activities positively influence market growth. The technological advancements and strong presence of pipeline drugs catalyze market growth. The growth in the number of cigarette smoking, alcohol & tobacco consumption boosts the global market growth. The heavy investments by pharmaceutical companies in developing various innovative therapies create a positive outlook for the market. Increasing awareness about the benefits of head and neck cancer drugs propels the market growth. Access to advanced healthcare facilities drives the market growth. The demand for immunotherapy is growing. The high preference for immunotherapy drugs over traditional chemotherapy strengthens market growth.  

Market Opportunity: Rapid adoption of the latest technologies in the drug development 

The rapid adoption of advanced technologies in the drug development process offers numerous opportunities for market growth. In line with this, manufacturers are adopting advanced technologies, such as artificial intelligence and data analytics, to research and produce head and neck cancer drugs. The improved quality of these drugs and the enhanced production catalyze market growth. 

Market Restraint: Side-effects 

There are many side effects associated with chemotherapy which is expected to restrict the head and neck cancer drugs market growth. In line with this, chemotherapy and radiation therapy are used to treat head and neck cancer. It is associated with various side effects, such as hair loss, faulty speech, and loss of normal voice. The patients may also face difficulties in eating. These side effects are anticipated to hinder the market growth during the forecast period. 

Market Challenge: Lack of healthcare facilities 

The lack of advanced healthcare infrastructure and facilities in developing and underdeveloped countries challenges market growth. The high costs of head and neck drugs hamper the market growth.

Related Reports

Key Developments: 

  • In March 2021, Merck KGaA collaborated with Debiopharm to develop and commercialize xevinapant. It is an inhibitor that helps in the advanced squamous cell carcinoma of the head and neck. 
  • In March 2021, Immutep Limited partnered with Merck & Co Inc subsidiaries to develop an innovative drug. This drug will be used to treat patients with head and neck squamous cell carcinoma (HNSCC) and to evaluate the efficacy of its lead product candidate, eftilagimod.  
  • In February 2021, Nektar Therapeutics partnered with SFJ Pharmaceuticals to develop a Bempegaldesleukin drug for treating head and neck cancer patients. 

Click Here to View Full Report Table of Contents

Thanks for reading you can also get individual chapter-wise sections or region-wise report versions such as North America, Europe, or the Asia Pacific.

Immediate Delivery Available | Buy This Premium Research Report@ https://www.precedenceresearch.com/checkout/1474

You can place an order or ask any questions, please feel free to contact at sales@precedenceresearch.com | +1 9197 992 333

 

Back to news